# Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

> **NCT03326063** · PHASE2 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 38 (actual)

## Conditions studied

- Nasal Polyps
- Asthma, Aspirin-Induced
- Aspirin-exacerbated Respiratory Disease
- Aspirin-Sensitive Asthma With Nasal Polyps

## Interventions

- **DRUG:** Ifetroban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03326063
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-26
- **Primary completion:** 2022-03-30
- **Final completion:** 2023-04-15
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03326063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03326063, "Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03326063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*